Drugs / antineoplaston AS2-1
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00003485 | Apr 1996 → May 2003 | colon carcinoma | Burzynski Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT00003517 | — | prostate adenocarcinoma | Burzynski Research Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT00003502 | — | mantle cell lymphoma | Burzynski Research Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT00003514 | — | cutaneous neuroendocrine carcinoma, pancreatic endocrine carcinoma, pituitary tumor | Burzynski Research Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT00003455 | — | female breast carcinoma | Burzynski Research Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT00003486 | — | colon adenocarcinoma | Burzynski Research Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT00003505 | — | primary central nervous system lymphoma | Burzynski Research Institute | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | antineoplaston AS2-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003502 ↗ |
| Known as | AS2-1 | “The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals.” NCT00003485 ↗ |
| Action | Inhibit | “Antineoplastons may inhibit the growth of cancer cells.” NCT00003486 ↗ |
| Route | Oral | “Patients receive oral antineoplaston A10 and antineoplaston AS2-1 6 to 7 times per day.” NCT00003455 ↗ |